New pill targets Tough-to-Treat prostate cancer in early trial
NCT ID NCT07172126
Summary
This early-stage study is testing a new oral medication called TQB3201 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone-blocking treatments. The main goals are to find a safe dose, see how the body processes the drug, and get an early look at whether it can help control the cancer. About 291 participants with specific types of advanced prostate cancer will help researchers understand if this new approach is promising for future treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Affiliated to Chongqing University
Chongqing, Chongqing Municipality, 400000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 201321, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, 519000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.